Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
Pulmonary Disease, Chronic Obstructive
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive focused on measuring Tolerability, Pharmacodynamics, Safety, Pharmacokinetics, GW642444, Asthmatic patients, Efficacy
Eligibility Criteria
Inclusion criteria: Subjects with a documented history of persistent asthma. Current non-smokers. Clinically stable persistent asthma FEV1 between 60 and 90% of predicted values. Inhaled corticosteroid therapy at a total daily dose between 200-500mcg of fluticasone or equivalent. Exclusion criteria: Subjects with significant past or present disease which which may affect their safety. Upper or lower respiratory tract infection within 4 weeks of screening. History of life threatening asthma, or asthma requiring treatment with oral corticosteroids within 3 months of study. Patients taking doses of inhaled corticosteroid >500mcg/day and patients who have changed therapy within 8 weeks of the study. Patients weighing less than 50kg.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
GW642444
Salmeterol